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INTRODUCTION: The use of injectable 
scaffolds has raised great interest as they minimise 
the need for invasive surgery and its associated 
complications, costs and discomfort to the patient. 
Furthermore, they can fill cavities of any size or 
shape as well as being able to deliver a localised 
therapeutic agent [1]. The aim of this study was to 
develop an injectable scaffold using PLGA 
microparticles which may be able to (i) carry cells 
and/or drugs to a site of injury (ii) be delivered via 
a narrow bore needle, and (iii) form a scaffold in 
situ with sufficient mechanical properties. The 
investigated system exploits a novel in situ 
solidification mechanism (liquid sintering) 
whereby the injectable microparticle-based 
precursors solidify into 3D constructs in response 
to thermal changes [2]. Thus, we demonstrate that 
PLGA microparticles incorporated with Triton X-
100 are thermally responsive at body temperature 
(37°C) and may be exploited in regenerative 
medical applications. 
METHODS: PLGA microparticles (<50µm and 
50-100µm diameter) were fabricated using the 
single emulsion (oil-in-water; O/W) technique. 
Triton X-100 incorporated microparticles were 
fabricated using the double emulsion (water-oil-
water; W/O/W) technique. Mechanical, rheological 
and injectability (27-gauge needle) characteristics 
of these microparticles were also documented. 
Fabricated microparticles were left to sinter at 
37°C and 60°C (temperature above Tg) for 24h 
before being evaluated using a Joel 6060LV 
variable pressure SEM operating at 10kV. The 
attachment, spreading and proliferation 
characteristics of Swiss 3T3 cells on the 
microparticles were also investigated. Moreover, 
the biocompatibility of these scaffolds was 
assessed using the chick chorioallantoic membrane 
(CAM) assay. 
RESULTS: Injectability of these microparticles 
(both size fractions) through the 27-gauge needle 
was feasible; although injectability of the 
suspension decreased with an increase in 
microparticle concentration. The rheological and 
mechanical profiles of the microparticles also 
expressed favourable transition characteristics. 
PLGA microparticles with Triton X-100  
incorporated were found to sinter into matrices at 
both 37°C and 60°C while microparticles without 
Triton X-100 incorporated did not undergo liquid 
sintering at 37°C (Fig 1). Triton X-100 
incorporated microparticles did not sinter at room 
temperature. 
 
Fig. 1: SEM micrographs of PLGA microparticles 
with 0%, 10% and 15% Triton X-100 incorporated 
after liquid sintering at 37°C (top row) and 60°C 
(bottom row)  
DISCUSSION & CONCLUSIONS: Injectability 
of the microparticles improved with higher liquid-
to-particle ratio by mass. Interestingly the size 
fractions had no significant effects on their 
injectability through a 27-gauge needle (p>0.05). 
The sintering effect at both 37°C and 60°C was 
induced by the presence of Triton X-100 and the 
consequent fusing between neighbouring 
microparticles into a 3D construct. Moreover, due 
to the low concentration of Triton X-100 exploited, 
incorporation efficiency and also leaching 
characteristics, initial cell and CAM assay analyses 
indicate that this novel self-sintering system may 
be biocompatible and not inhibit angiogenesis.  
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